What is the recommended once daily (QD) dosing of cefdinir for community-acquired pneumonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefdinir Dosing for Community-Acquired Pneumonia

For community-acquired pneumonia, cefdinir should be administered at 300 mg twice daily for 10 days in adults. 1

Adult Dosing Recommendations

  • Cefdinir 300 mg twice daily for 10 days is the recommended regimen for adults with community-acquired pneumonia, showing approximately 90% clinical cure rates 1
  • Alternatively, cefdinir 600 mg once daily for 10 days can also be effective for community-acquired pneumonia in adults 2
  • Treatment duration should generally not exceed 8 days in a responding patient, according to lower respiratory tract infection guidelines 3

Efficacy and Evidence

  • Clinical studies have demonstrated that cefdinir (300 mg twice daily or 600 mg once daily) has clinical and bacteriological efficacy equivalent to other oral agents in community-acquired pneumonia 2
  • In a randomized, double-blind trial comparing cefdinir with cefaclor in community-acquired pneumonia, cefdinir achieved a satisfactory clinical response (cure plus improvement) in 89% of evaluable patients 1
  • Microbiological eradication rates with cefdinir were 92% in community-acquired pneumonia, comparable to other antibiotics 1

Clinical Considerations

  • Cefdinir has good in vitro activity against common respiratory pathogens including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis 4
  • The drug distributes well into respiratory tract tissues and fluids, making it suitable for respiratory infections 2
  • Cefdinir is stable to hydrolysis by commonly occurring plasmid-mediated beta-lactamases and retains good activity against beta-lactamase-producing strains of H. influenzae and M. catarrhalis 4

Pediatric Dosing

  • For children, cefdinir is dosed at 14 mg/kg/day in one or two daily doses 2
  • For children 1-9 years old: 5 mg/kg/day once daily, not to exceed 150 mg 3
  • For children ≥10 years old: 200 mg/day as single daily dose or in 2 doses 3

Safety and Tolerability

  • Diarrhea is the most common adverse event with cefdinir, occurring in approximately 20% of patients 5
  • Despite higher incidence of diarrhea compared to some comparators, discontinuation rates due to adverse events are generally similar between cefdinir and other antibiotics 4
  • Cefdinir has shown superior taste or palatability over other oral antimicrobial agents, which may improve adherence 2

Important Considerations and Pitfalls

  • Cefdinir may not be the first-line agent for community-acquired pneumonia according to current guidelines, which typically recommend amoxicillin, macrolides, or respiratory fluoroquinolones depending on patient characteristics 6, 7
  • For severe community-acquired pneumonia requiring hospitalization, parenteral therapy with β-lactam plus macrolide is generally recommended rather than oral cephalosporins like cefdinir 3, 7
  • Patients should be monitored for clinical improvement within 48-72 hours; if deterioration occurs or no improvement is seen, further investigation and potential therapy change should be considered 3

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.